Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations
- PMID: 21936714
- DOI: 10.1089/aid.2010.0363
Short communication: HIV antigen-specific reactivation of HIV infection from cellular reservoirs: implications in the settings of therapeutic vaccinations
Abstract
Therapeutic vaccinations using human immunodeficiency virus (HIV) antigens in HIV-infected patients on antiretroviral therapy (ART) have so far been attempted with the purpose of inducing CTL response. However, they can also be useful as a strategy for activation of latent HIV reservoir, which is thought to be mainly comprised of latently infected HIV-specific memory CD4 cells, eventually leading to elimination of the virus. The present study was carried out to explore the ability of different HIV antigens to activate HIV replication as assessed by intracellular P24 detection as well as to induce T cell responses in terms of cytokine expression by flow cytometry after stimulation of PBMCs from HIV-infected patients. HIV antigens were found to be able to activate most of the CD4 T cells harboring proviral DNA. HIV-1 Pol and Env were responsible for induction of higher HIV replication in terms of both magnitude and frequency followed by Gag and Nef. As opposed to this, Pol and Env contributed to fewer numbers of polyfunctional CD8 cells desirable for elimination of HIV-infected cells in comparison to Gag and Nef. Thus, HIV antigens may provide a strategy for the activation of a latent reservoir. It was observed that HIV replication started as early as half an hour after in vitro activation indicating a stringent need for maintaining effective concentrations of antiretroviral drugs to prevent further spread of HIV during this process. HIV-infected cells were found to be responsible for higher IL-10 secretion after activation, which could also serve as one of the reasons for suppressed CD8 responses to Pol and Env as more HIV-infected CD4 cells would be secreting IL-10 in response to these antigens. Since IL-10 blockade helped to improve immune responses in terms of cytokine secretion, it should be considered in settings of therapeutic vaccination to improve CTL responses, which will ultimately limit the persistence of the viral reservoir.
Similar articles
-
HIV-1 reservoir dynamics in CD4+ T cells.Curr Opin HIV AIDS. 2019 Mar;14(2):108-114. doi: 10.1097/COH.0000000000000521. Curr Opin HIV AIDS. 2019. PMID: 30531293 Review.
-
Impact of antiretroviral and tuberculosis therapies on CD4+ and CD8+ HIV/M. tuberculosis-specific T-cell in co-infected subjects.Immunol Lett. 2018 Jun;198:33-43. doi: 10.1016/j.imlet.2018.04.001. Epub 2018 Apr 7. Immunol Lett. 2018. PMID: 29635002
-
Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.Vaccine. 2013 Aug 12;31(36):3739-46. doi: 10.1016/j.vaccine.2013.05.021. Epub 2013 May 21. Vaccine. 2013. PMID: 23707169 Clinical Trial.
-
Antiretroviral therapy-induced dominant interleukin-2 HIV-1 Gag CD4+ T cell response: evidence of functional recovery of HIV-1-specific CD4+ T cells.Scand J Immunol. 2011 Mar;73(3):256-65. doi: 10.1111/j.1365-3083.2010.02502.x. Scand J Immunol. 2011. PMID: 21204901
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
Cited by
-
Experimental models for HIV latency and molecular tools for reservoir quantification-an update.Clin Microbiol Rev. 2023 Dec 20;36(4):e0001323. doi: 10.1128/cmr.00013-23. Epub 2023 Nov 15. Clin Microbiol Rev. 2023. PMID: 37966222 Review.
-
Antiretroviral Treatment-Induced Galectin-9 Might Impact HIV Viremia in Addition to Contributing to Inflammaging.Int J Mol Sci. 2023 Jul 31;24(15):12273. doi: 10.3390/ijms241512273. Int J Mol Sci. 2023. PMID: 37569647 Free PMC article.
-
Addressing an HIV cure in LMIC.Retrovirology. 2021 Aug 3;18(1):21. doi: 10.1186/s12977-021-00565-1. Retrovirology. 2021. PMID: 34344423 Free PMC article. Review.
-
Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.Front Immunol. 2021 Apr 30;12:663919. doi: 10.3389/fimmu.2021.663919. eCollection 2021. Front Immunol. 2021. PMID: 33995393 Free PMC article.
-
Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents.Retrovirology. 2020 Nov 23;17(1):36. doi: 10.1186/s12977-020-00545-x. Retrovirology. 2020. PMID: 33228686 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials